Tackling immunosuppression by Neisseria gonorrhoeae to facilitate vaccine design
PLOS Pathogens · 14.11.2024 · 20 (11) · e1012688
DOI: 10.1371/journal.ppat.1012688 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, online erschienen am 14.11.2024. Verfasst von Rebekah A Jones und 12 weiteren Autor:innen. Beteiligte Einrichtung: Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford, United Kingdom. Hauptthemen laut MEDLINE: Neisseria gonorrhoeae, Gonorrhea. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: Wellcome Trust.
Abstract (Originalsprache)
Gonorrhoea, caused by Neisseria gonorrhoeae , is a common sexually transmitted infection. Increasing multi-drug resistance and the impact of asymptomatic infections on sexual and reproductive health underline the need for an effective gonococcal vaccine. Outer membrane vesicles (OMVs) from Neisseria meningitidis induce modest cross-protection against gonococcal infection. However, the presence of proteins in OMVs derived from N . gonorrhoeae that manipulate immune responses could hamper their success as a vaccine. Here we modified two key immunomodulatory proteins of the gonococcus; RmpM, which can elicit ‘blocking antibodies’, and PorB, an outer membrane porin which contributes to immunosuppression. As meningococcal PorB has adjuvant properties, we replaced gonococcal PorB with a meningococcal PorB. Immunisation with OMVs from N . gonorrhoeae lacking rmpM and expressing meningococcal porB elicited higher antibody titres against model antigens in mice compared to OMVs with native PorB. Further, a gonococcal protein microarray revealed stronger IgG antibody responses to a more diverse range of antigens in the Nm PorB OMV immunised group. Finally, meningococcal PorB OMVs resulted in a Th1-skewed response, exemplified by increased serum IgG2a antibody responses and increased IFNɣ production by splenocytes from immunised mice. In summary, we demonstrate that the replacement of PorB in gonococcal OMVs enhances immune responses and offers a strategy for gonococcal vaccine development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford, United Kingdom.
- School of Biological Sciences, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester United Kingdom.
- Medicines and Healthcare products Regulatory Agency, South Mimms, Potters Bar, Hertfordshire, United Kingdom.
- Department of Microbiology and Immunology, Uniformed Services University, Bethesda, Maryland, United States of America.
ORCID-Profile: Christoph M Tang
Förderung
- Wellcome Trust
Zitieren
APA
Jones, R. A., Ramirez-Bencomo, F., Whiting, G., Fang, M., Lavender, H., Kurzyp, K., Thistlethwaite, A., Stejskal, L., Rashmi, S., Jerse, A. E., Cehovin, A., Derrick, J. P., & Tang, C. M. (2024). Tackling immunosuppression by Neisseria gonorrhoeae to facilitate vaccine design. PLOS Pathogens, 20(11), e1012688. https://doi.org/10.1371/journal.ppat.1012688
Vancouver
Jones RA, Ramirez-Bencomo F, Whiting G, Fang M, Lavender H, Kurzyp K, et al. Tackling immunosuppression by Neisseria gonorrhoeae to facilitate vaccine design. PLOS Pathogens. 2024;20(11):e1012688. doi:10.1371/journal.ppat.1012688
BibTeX
@article{Jones2024,
author = {Jones, Rebekah A and Ramirez-Bencomo, Fidel and Whiting, Gail and Fang, Min and Lavender, Hayley and Kurzyp, Kacper and Thistlethwaite, Angela and Stejskal, Lenka and Rashmi, Smruti and Jerse, Ann E and Cehovin, Ana and Derrick, Jeremy P and Tang, Christoph M},
title = {Tackling immunosuppression by Neisseria gonorrhoeae to facilitate vaccine design},
journal = {PLOS Pathogens},
year = {2024},
volume = {20},
number = {11},
pages = {e1012688},
doi = {10.1371/journal.ppat.1012688}
}
EUVIMED